Prolyl Hydroxylase-3 is a Novel Renal Cell Carcinoma Biomarker

Overview

Journal Investig Clin Urol

Specialty Urology

Date 2019 Nov 7

PMID 31692952

Citations 5

Authors

Kwang Hyun Kim

Hyung Ho Lee

Young Eun Yoon

Joon Chae Na

Kyung Sup Kim

Woong Kyu Han

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study was to determine the suitability of serum prolyl hydroxylase-3 (PHD3) as a diagnostic or monitoring biomarker of renal cell carcinoma (RCC).

Materials And Methods: Between October 2013 and March 2015, we prospectively recruited study participants. The RCC group consisted of 56 patients who underwent radical or partial nephrectomy. The control group included 56 healthy kidney donors and 13 patients with benign renal masses. Blood from the RCC patients was sampled prior to surgery and again 1 and 3 months after the operation. Serum PHD3 levels were measured via enzyme-linked immunosorbent assay and compared between RCC patients and controls.

Results: RCC patients had higher serum PHD3 levels than controls (0.79±0.17 ng/mL vs. 0.73±0.09 ng/mL, p=0.023), with an area under curve (AUC) of 0.668. With a cutoff value of 0.761 ng/ml, the sensitivity, specificity, positive predictive value, and negative predictive value were 66.1%, 68.1%, 28.8%, and 37.3%, respectively. No significant difference in PHD3 level was observed between healthy kidney donors and patients with benign renal masses. The predictive performance of PHD3 was improved in subgroup analyses of RCC patients with a tumor size >2 cm (n=40) or clear-cell histology (n=44), with AUCs of 0.709 and 0.688, respectively. Among 37 patients with PHD3 levels greater than the cutoff value of 0.761 ng/mL, the postoperative PHD3 levels at 1 and 3 months were significantly lower than the preoperative PHD3 levels (both p<0.001).

Conclusions: Serum PHD3 represents a novel RCC biomarker that shows acceptable diagnostic performance.

Citing Articles

Low nuclear expression of HIF-hydroxylases PHD2/EGLN1 and PHD3/EGLN3 are associated with poor recurrence-free survival in clear cell renal cell carcinoma.

Luomala L, Mattila K, Vainio P, Nisen H, Pellinen T, Lohi J Cancer Med. 2024; 13(3):e6998.

PMID: 38400673 PMC: 10891444. DOI: 10.1002/cam4.6998.

Canadian Urological Association guideline: Management of small renal masses - Full-text.

Richard P, Violette P, Bhindi B, Breau R, Kassouf W, Lavallee L Can Urol Assoc J. 2022; 16(2):E61-E75.

PMID: 35133268 PMC: 8932428. DOI: 10.5489/cuaj.7763.

Discovery and construction of prognostic model for clear cell renal cell carcinoma based on single-cell and bulk transcriptome analysis.

Zhang F, Yu S, Wu P, Liu L, Wei D, Li S Transl Androl Urol. 2021; 10(9):3540-3554.

PMID: 34733651 PMC: 8511535. DOI: 10.21037/tau-21-581.

Renal tumor biomarkers (Review).

Bratu O, Mischianu D, Marcu D, Spinu D, Iorga L, Cherciu A Exp Ther Med. 2021; 22(5):1297.

PMID: 34630652 PMC: 8461509. DOI: 10.3892/etm.2021.10732.

Circ_101341 Deteriorates the Progression of Clear Cell Renal Cell Carcinoma Through the miR- 411/EGLN3 Axis.

Yue Y, Cui J, Zhao Y, Liu S, Niu W Cancer Manag Res. 2021; 12:13513-13525.

PMID: 33408523 PMC: 7781030. DOI: 10.2147/CMAR.S272287.

References

Amatschek S, Koenig U, Auer H, Steinlein P, Pacher M, Gruenfelder A . Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res. 2004; 64(3):844-56. DOI: 10.1158/0008-5472.can-03-2361. View

Schodel J, Grampp S, Maher E, Moch H, Ratcliffe P, Russo P . Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer. Eur Urol. 2015; 69(4):646-657. PMC: 5012644. DOI: 10.1016/j.eururo.2015.08.007. View

Cui L, Qu J, Dang S, Mao Z, Wang X, Fan X . Prolyl hydroxylase 3 inhibited the tumorigenecity of gastric cancer cells. Mol Carcinog. 2013; 53(9):736-43. DOI: 10.1002/mc.22025. View

Dong D, Jia L, Zhou Y, Ren L, Li J, Zhang J . Serum level of ANGPTL4 as a potential biomarker in renal cell carcinoma. Urol Oncol. 2017; 35(5):279-285. DOI: 10.1016/j.urolonc.2016.12.017. View

Go A, Chertow G, Fan D, McCulloch C, Hsu C . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351(13):1296-305. DOI: 10.1056/NEJMoa041031. View

Weiss R, Lin P . Kidney cancer: identification of novel targets for therapy. Kidney Int. 2006; 69(2):224-32. DOI: 10.1038/sj.ki.5000065. View

Jokilehto T, Jaakkola P . The role of HIF prolyl hydroxylases in tumour growth. J Cell Mol Med. 2010; 14(4):758-70. PMC: 3823110. DOI: 10.1111/j.1582-4934.2010.01030.x. View

Miikkulainen P, Hogel H, Rantanen K, Suomi T, Kouvonen P, Elo L . HIF prolyl hydroxylase PHD3 regulates translational machinery and glucose metabolism in clear cell renal cell carcinoma. Cancer Metab. 2017; 5:5. PMC: 5496173. DOI: 10.1186/s40170-017-0167-y. View

Fox S, Generali D, Berruti A, Brizzi M, Campo L, Bonardi S . The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen. Breast Cancer Res. 2011; 13(1):R16. PMC: 3109585. DOI: 10.1186/bcr2825. View

10.

Schofield C, Ratcliffe P . Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004; 5(5):343-54. DOI: 10.1038/nrm1366. View

11.

Mole D, Blancher C, Copley R, Pollard P, Gleadle J, Ragoussis J . Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem. 2009; 284(25):16767-16775. PMC: 2719312. DOI: 10.1074/jbc.M901790200. View

12.

Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M . HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001; 292(5516):464-8. DOI: 10.1126/science.1059817. View

13.

Tanaka T, Torigoe T, Hirohashi Y, Sato E, Honma I, Kitamura H . Hypoxia-inducible factor (HIF)-independent expression mechanism and novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma. J Cancer Res Clin Oncol. 2014; 140(3):503-13. DOI: 10.1007/s00432-014-1593-7. View

14.

Cerami E, Gao J, Dogrusoz U, Gross B, Sumer S, Aksoy B . The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5):401-4. PMC: 3956037. DOI: 10.1158/2159-8290.CD-12-0095. View

15.

Andersen S, Donnem T, Stenvold H, Al-Saad S, Al-Shibli K, Busund L . Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival. PLoS One. 2011; 6(8):e23847. PMC: 3161788. DOI: 10.1371/journal.pone.0023847. View

16.

Isaacs J, Jung Y, Mole D, Lee S, Torres-Cabala C, Chung Y . HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell. 2005; 8(2):143-53. DOI: 10.1016/j.ccr.2005.06.017. View

17.

Sato E, Torigoe T, Hirohashi Y, Kitamura H, Tanaka T, Honma I . Identification of an immunogenic CTL epitope of HIFPH3 for immunotherapy of renal cell carcinoma. Clin Cancer Res. 2008; 14(21):6916-23. DOI: 10.1158/1078-0432.CCR-08-0466. View

18.

Su Y, Loos M, Giese N, Hines O, Diebold I, Gorlach A . PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer. Br J Cancer. 2010; 103(10):1571-9. PMC: 2990580. DOI: 10.1038/sj.bjc.6605936. View

19.

Gossage L, Zaitoun A, Fareed K, Turley H, Aloysius M, Lobo D . Expression of key hypoxia sensing prolyl-hydroxylases PHD1, -2 and -3 in pancreaticobiliary cancer. Histopathology. 2010; 56(7):908-20. DOI: 10.1111/j.1365-2559.2010.03566.x. View

20.

Xue J, Li X, Jiao S, Wei Y, Wu G, Fang J . Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity. Gastroenterology. 2009; 138(2):606-15. DOI: 10.1053/j.gastro.2009.09.049. View